Document Detail


Quality of life and other patient-reported outcomes following pelvic exenteration for pelvic malignancy.
MedLine Citation:
PMID:  24420909     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Pelvic exenteration is highly radical surgery offering the only potential cure for locally advanced pelvic cancer. This study compared quality of life and other relevant patient-reported outcomes over 12 months for patients who did and those who did not undergo pelvic exenteration.
METHODS: Consecutive patients referred for consideration of pelvic exenteration completed clinical and patient-reported outcome assessments at baseline, hospital discharge (exenteration patients only), and 1, 3, 6, 9 and 12 months. Outcomes included cancer-specific quality of life (Functional Assessment of Cancer Therapy - Colorectal; FACT-C), physical and mental health status (Short Form 36 version 2), psychological distress (Distress Thermometer), and pain (study-specific composite) scores. Linear mixed modelling compared trajectories between exenteration and no-exenteration groups.
RESULTS: Among 182 patients, 148 (81.3 per cent) proceeded to exenteration. There were no baseline differences between the two groups. Among patients who had exenteration, the mean FACT-C score at baseline of 93.0 had reduced by 14·4 points at hospital discharge, but increased to 86·7 at 1 month after surgery and continued to improve, returning to baseline by 9 months. For patients in the no-exenteration group, FACT-C scores decreased between baseline and 1 month, increased slowly to 6 months and then began to decline at 9 months. There were few statistically or clinically significant differences in any patient-reported outcomes between the groups.
CONCLUSION: Quality of life and related patient-reported outcomes improve rapidly after pelvic exenteration surgery. For 9 months after surgery, these outcomes are comparable with those of similar do patients who do not have surgery; thereafter, there is a decline in patients who do not have exenteration. Pelvic exenteration can be performed with acceptable quality of life and patient-reported outcomes.
Authors:
J M Young; T Badgery-Parker; L M Masya; M King; C Koh; A C Lynch; A G Heriot; M J Solomon
Related Documents :
24506529 - Microwave endometrial ablation versus thermal balloon endometrial ablation (meatball): ...
16600829 - A description of intraoperative and postanesthesia complication rates.
17549629 - Protective effects of baicalin and octreotide on multiple organ injury in severe acute ...
23929509 - Outcome after modified putti-platt procedure for recurrent traumatic anterior shoulder ...
16795979 - Operative morbidity and mortality after d2 and d4 extended dissection for advanced gast...
24296869 - Ivabradine improves quality of life in subjects with chronic heart failure compared to ...
8517839 - Clinical analysis of 125 patients with the lupus anticoagulant.
16616029 - Effect of radiofrequency catheter ablation for atrial fibrillation on left atrial cavit...
11952579 - Randomized clinical trial assessing the side-effects of glyceryl trinitrate and diltiaz...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-1-13
Journal Detail:
Title:  The British journal of surgery     Volume:  -     ISSN:  1365-2168     ISO Abbreviation:  Br J Surg     Publication Date:  2014 Jan 
Date Detail:
Created Date:  2014-1-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372553     Medline TA:  Br J Surg     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2014 BJS Society Ltd. Published by John Wiley & Sons, Ltd.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Morphological Effect on Fluorescence Behavior of Silver Nanoparticles.
Next Document:  Drug-Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucos...